Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial.
BACKGROUND
We and others have previously reported significant changes in chloride transport after cationic-lipid-mediated transfer of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to the nasal epithelium of patients with cystic fibrosis. We studied the safety and efficacy of this gene transfer to the lungs and nose of patients with cystic fibrosis in a double-blind placebo-controlled trial.


METHODS
Eight patients with cystic fibrosis were randomly assigned DNA-lipid complex (active) by nebulisation into the lungs followed 1 week later by administration to the nose. Eight control patients followed the same protocol but with the lipid alone (placebo). Safety was assessed clinically, by radiography, by pulmonary function, by induced sputum, and by histological analysis. Efficacy was assessed by analysis of vector-specific CFTR DNA and mRNA, in-vivo potential difference, epifluorescence assay of chloride efflux, and bacterial adherence.


RESULTS
Seven of the eight patients receiving the active complex reported mild influenza-like symptoms that resolved within 36 h. Six of eight patients in both the active and placebo groups reported mild airway symptoms over a period of 12 h following pulmonary administration. No specific treatment was required for either event. Pulmonary administration resulted in a significant (p<0.05) degree of correction of the chloride abnormality in the patients receiving active treatment but not in those on placebo when assessed by in-vivo potential difference and chloride efflux. Bacterial adherence was also reduced. We detected no alterations in the sodium transport abnormality. A similar pattern occurred following nasal administration.


CONCLUSIONS
Cationic-lipid-mediated CFTR gene transfer can significantly influence the underlying chloride defect in the lungs of patients with cystic fibrosis.
Alton
E W
EW
Department of Gene Therapy, Imperial College at National Heart and Lung Institute, London, UK. e.alton@ic.ac.uk
Stern
M
M
Farley
R
R
Jaffe
A
A
Chadwick
S L
SL
Phillips
J
J
Davies
J
J
Smith
S N
SN
Browning
J
J
Davies
M G
MG
Hodson
M E
ME
Durham
S R
SR
Li
D
D
Jeffery
P K
PK
Scallan
M
M
Balfour
R
R
Eastman
S J
SJ
Cheng
S H
SH
Smith
A E
AE
Meeker
D
D
Geddes
D M
DM
D000328:Adult; D001422:Bacterial Adhesion; D002712:Chlorides / Q000378:metabolism; D003550:Cystic Fibrosis / Q000000981:diagnostic imaging / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D018076:DNA, Complementary / Q000032:analysis / Q000235:genetics; D004311:Double-Blind Method; D004848:Epithelium / Q000378:metabolism; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D008055:Lipids; D008168:Lung / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D009297:Nasal Mucosa / Q000378:metabolism; D009330:Nebulizers and Vaporizers; D010919:Placebos; D012333:RNA, Messenger / Q000032:analysis; D011859:Radiography; D012449:Safety; D013183:Sputum / Q000378:metabolism
C505032:CFTR protein, human; D002712:Chlorides; D018076:DNA, Complementary; D008055:Lipids; D010919:Placebos; D012333:RNA, Messenger; D019005:Cystic Fibrosis Transmembrane Conductance Regulator